Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs

Isabella Monia Montagner, Anna Merlo, Gaia Zuccolotto, Davide Renier, Monica Campisi, Gianfranco Pasut, Paola Zanovello, Antonio Rosato

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunocompromised mice with bioconjugates formed by chemical linking of paclitaxel or SN-38 to hyaluronan, against three models of peritoneal carcinomatosis derived from human colorectal, gastric and esophageal tumor cell xenografts. In vitro, bioconjugates were selectively internalized through mechanisms largely dependent on interaction with the CD44 receptor and caveolin-mediated endocytosis, which led to accumulation of compounds into lysosomes of tumor cells. Moreover, they inhibited tumor growth comparably to free drugs. In vivo, efficacy of bioconjugates or free drugs against luciferase-transduced tumor cells was assessed by bioluminescence optical imaging, and by recording mice survival. The intraperitoneal administration of bioconjugates in tumor-bearing mice exerted overlapping or improved therapeutic efficacy compared with unconjugated drugs. Overall, drug conjugation to hyaluronan significantly improved the profiles of in vivo tolerability and widened the field of application of existing drugs, over their formal approval or current use. Therefore, this approach can be envisaged as a promising therapeutic strategy for locoregional treatment of peritoneal carcinomatosis.

Original languageEnglish
Article numbere112240
JournalPLoS One
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 10 2014

Fingerprint

hyaluronic acid
Hyaluronic Acid
Tumors
Pharmacology
Carcinoma
drugs
therapeutics
neoplasms
Cells
Pharmaceutical Preparations
Neoplasms
irinotecan
mice
Bearings (structural)
Therapeutics
Caveolins
Bioluminescence
esophageal neoplasms
paclitaxel
stomach neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Peritoneal tumor carcinomatosis : Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. / Montagner, Isabella Monia; Merlo, Anna; Zuccolotto, Gaia; Renier, Davide; Campisi, Monica; Pasut, Gianfranco; Zanovello, Paola; Rosato, Antonio.

In: PLoS One, Vol. 9, No. 11, e112240, 10.11.2014.

Research output: Contribution to journalArticle

Montagner, Isabella Monia ; Merlo, Anna ; Zuccolotto, Gaia ; Renier, Davide ; Campisi, Monica ; Pasut, Gianfranco ; Zanovello, Paola ; Rosato, Antonio. / Peritoneal tumor carcinomatosis : Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. In: PLoS One. 2014 ; Vol. 9, No. 11.
@article{14f604f621d74563b26ae531508b6a97,
title = "Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs",
abstract = "Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunocompromised mice with bioconjugates formed by chemical linking of paclitaxel or SN-38 to hyaluronan, against three models of peritoneal carcinomatosis derived from human colorectal, gastric and esophageal tumor cell xenografts. In vitro, bioconjugates were selectively internalized through mechanisms largely dependent on interaction with the CD44 receptor and caveolin-mediated endocytosis, which led to accumulation of compounds into lysosomes of tumor cells. Moreover, they inhibited tumor growth comparably to free drugs. In vivo, efficacy of bioconjugates or free drugs against luciferase-transduced tumor cells was assessed by bioluminescence optical imaging, and by recording mice survival. The intraperitoneal administration of bioconjugates in tumor-bearing mice exerted overlapping or improved therapeutic efficacy compared with unconjugated drugs. Overall, drug conjugation to hyaluronan significantly improved the profiles of in vivo tolerability and widened the field of application of existing drugs, over their formal approval or current use. Therefore, this approach can be envisaged as a promising therapeutic strategy for locoregional treatment of peritoneal carcinomatosis.",
author = "Montagner, {Isabella Monia} and Anna Merlo and Gaia Zuccolotto and Davide Renier and Monica Campisi and Gianfranco Pasut and Paola Zanovello and Antonio Rosato",
year = "2014",
month = "11",
day = "10",
doi = "10.1371/journal.pone.0112240",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Peritoneal tumor carcinomatosis

T2 - Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs

AU - Montagner, Isabella Monia

AU - Merlo, Anna

AU - Zuccolotto, Gaia

AU - Renier, Davide

AU - Campisi, Monica

AU - Pasut, Gianfranco

AU - Zanovello, Paola

AU - Rosato, Antonio

PY - 2014/11/10

Y1 - 2014/11/10

N2 - Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunocompromised mice with bioconjugates formed by chemical linking of paclitaxel or SN-38 to hyaluronan, against three models of peritoneal carcinomatosis derived from human colorectal, gastric and esophageal tumor cell xenografts. In vitro, bioconjugates were selectively internalized through mechanisms largely dependent on interaction with the CD44 receptor and caveolin-mediated endocytosis, which led to accumulation of compounds into lysosomes of tumor cells. Moreover, they inhibited tumor growth comparably to free drugs. In vivo, efficacy of bioconjugates or free drugs against luciferase-transduced tumor cells was assessed by bioluminescence optical imaging, and by recording mice survival. The intraperitoneal administration of bioconjugates in tumor-bearing mice exerted overlapping or improved therapeutic efficacy compared with unconjugated drugs. Overall, drug conjugation to hyaluronan significantly improved the profiles of in vivo tolerability and widened the field of application of existing drugs, over their formal approval or current use. Therefore, this approach can be envisaged as a promising therapeutic strategy for locoregional treatment of peritoneal carcinomatosis.

AB - Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunocompromised mice with bioconjugates formed by chemical linking of paclitaxel or SN-38 to hyaluronan, against three models of peritoneal carcinomatosis derived from human colorectal, gastric and esophageal tumor cell xenografts. In vitro, bioconjugates were selectively internalized through mechanisms largely dependent on interaction with the CD44 receptor and caveolin-mediated endocytosis, which led to accumulation of compounds into lysosomes of tumor cells. Moreover, they inhibited tumor growth comparably to free drugs. In vivo, efficacy of bioconjugates or free drugs against luciferase-transduced tumor cells was assessed by bioluminescence optical imaging, and by recording mice survival. The intraperitoneal administration of bioconjugates in tumor-bearing mice exerted overlapping or improved therapeutic efficacy compared with unconjugated drugs. Overall, drug conjugation to hyaluronan significantly improved the profiles of in vivo tolerability and widened the field of application of existing drugs, over their formal approval or current use. Therefore, this approach can be envisaged as a promising therapeutic strategy for locoregional treatment of peritoneal carcinomatosis.

UR - http://www.scopus.com/inward/record.url?scp=84911375720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911375720&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0112240

DO - 10.1371/journal.pone.0112240

M3 - Article

C2 - 25383653

AN - SCOPUS:84911375720

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e112240

ER -